Apimeds Pharmaceuticals US Net Tangible Assets

Apimeds Pharmaceuticals US posts a net tangible assets of $130M as of March 2026. That compares with $-1.8M in the prior-year period — up 7286.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Apimeds Pharmaceuticals US's net tangible assets was $-1.8M. The latest reading is $130M — a 7286.3% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Net Tangible Assets is one piece of Apimeds Pharmaceuticals US's financial statement story. At $130M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for APUS's net tangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Apimeds Pharmaceuticals US's other metric pages and overview cover the third.